Efficacy of low-temperature argon plasma in the rehabilitation of patients undergoing radiation therapy for breast cancer
- Authors: Kozyreva V.O.1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 23, No 2 (2024)
- Pages: 91-100
- Section: Original studies
- URL: https://journals.rcsi.science/1681-3456/article/view/272302
- DOI: https://doi.org/10.17816/rjpbr639987
- ID: 272302
Cite item
Abstract
Background: During radiation therapy for breast cancer, healthy tissues are damaged, leading to both systemic and local reactions, including radiation dermatitis with such symptoms as erythema, dryness, peeling, and pain. Disturbances of the microcirculation lead to hypoxia and fibrosis. The use of low-temperature argon plasma is a promising method for preventing acute radiation-induced skin damage, which is crucial for maintaining quality of life, preventing complications, and minimizing long-term effects.
Aim: To evaluate the effectiveness of low-temperature argon plasma used in the complex medical rehabilitation of patients undergoing external radiation therapy for breast cancer.
Materials and methods: A prospective, randomized interventional study was conducted involving 60 breast cancer patients undergoing radiation therapy. All patients received a course of medical rehabilitation, including general magnetic therapy, exercise therapy, balance response training on a biofeedback simulator, nutritional support, and sessions with a medical psychologist. In the main group (n = 30), rehabilitation included low-temperature argon plasma treatment. Outcomes were assessed using the RTOG scale for acute complications of radiation therapy and laser Doppler flowmetry.
Results: After completing radiation therapy and complex medical rehabilitation, statistically significant differences were observed between the main group and the comparison group (which did not receive low-temperature argon plasma treatment) in the severity of radiation reactions on the RTOG scale (p = 0.016) and in peripheral blood flow parameters.
Conclusion: Low-temperature argon plasma supports nutritional blood flow and active mechanisms for microcirculatory regulation, preserving skin blood supply and preventing severe acute radiation dermatitis.
Full Text
##article.viewOnOriginalSite##About the authors
Valeriia O. Kozyreva
Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: kvo03@yandex.ru
ORCID iD: 0000-0002-1103-704X
SPIN-code: 6936-0576
Russian Federation, Moscow
References
- Velikaya VV, Startseva ZA, Goldberg VE, Popova NO. Ten-year results of complex treatment of patients with primary local advanced breast cancer. Med Radiol Radiat Safety = Meditsinskaia radiologiia i radiatsionnaia bezopasnost. 2023;68(5):71–76. EDN: KWHBTU doi: 10.33266/1024-6177-2023- 68-5-71-76
- Strunkin DN, Kononchuk VV, Gulyaeva LF, et al. Current aspects of systematics, diagnosis and treatment of breast cancer. Tumors Female Reproductive Syst. 2022;18(1):25–39. EDN: ZITHFA doi: 10.17650/1994-4098-2022-18-1-25-39
- Balaeva DA, Romanov DS, Trofimova OP, et al. Radiation injuries of organs and tissues: mechanisms of occurrence, methods of prevention and treatment: A review. Sovremennaya oncologya = J Modern Oncol. 2023;25(4):504–512. EDN: PDUTYF doi: 10.26442/18151434.2023.4.202572
- Balaeva DA, Romanov DS. Management of patients with acute radiation dermatitis. Current trends and clinical examples. Med Council = Meditsinsky sovet. 2022;16(22):103–110. EDN: NYSCFO doi: 10.21518/2079-701X-2022-16-22-103-110
- Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: A review of our current understanding. Am J Clin Dermatol. 2016;17(3):277–292. EDN: YDRAVW doi: 10.1007/s40257-016-0186-4
- Plaza D, Baic A, Lange B, et al. Correlation between isotherms and isodoses in breast cancer radiotherapy ― First study. Int J Environ Res Public Health. 2021;18(2):619. doi: 10.3390/ijerph18020619
- Evstigneeva IS, Kozyreva VO, Gerasimenko MY. Experience in the use of low-temperature plasma in the therapy of radiation reactions. Fizioterapiya, bal’neologiya i reabilitatsiya = Russ J Physical Therapy, Balneotherapy Rehab. 2021;20(6):559–566. EDN: AHSCCW doi: 10.17816/rjpbr108081
- Akishev YS. Non-thermal plasma at atmospheric pressure and its opportunities for applications. Izvestiya vysshikh uchebnykh zavedenii. Khimiya khimicheskaya tekhnologiya = Russ J Chemistry Chemical Technol. 2019;62(8):26−60. EDN: OEUOGV doi: 10.6060/ivkkt.20196208.5908
- Korotky VN. Feasibility of using cold atmospheric plasma in the treatment of cancer patients (literature review). Sibirskiy oncologicheskiy zhurnal = Siberian J Oncol. 2018;17(1):72–81. EDN: YQNNNU doi: 10.21294/1814-4861-2018-17-1-72-81
- Grushina TI, Zhavoronkova VV, Tkachenko GA, et al. A guide for doctors on the rehabilitation of breast cancer patients. J Modern Oncol. 2020;22(3):3–34. (In Russ.) EDN: AMTYTP doi: 10.26442/18151434.2020.3.200404
- Wang B, Wei J, Meng L, et al. Advances in pathogenic mechanisms and management of radiation-induced fibrosis. Biomed Pharmacother. 2020;121:109560. EDN: DWFISV doi: 10.1016/j.biopha.2019.109560
- Ma L, Chen Y, Gong Q, et al. Cold atmospheric plasma alleviates radiation-induced skin injury by suppressing inflammation and promoting repair. Free Radic Biol Med. 2023;(204):184–194. EDN: PAOKYD doi: 10.1016/j.freeradbiomed.2023.05.002
- Hartwig S, Doll C, Voss JO, et al. Treatment of wound healing disorders of radial forearm free flap donor sites using cold atmospheric plasma: A proof of concept. J Oral Maxillofacial Surg. 2017;75(2):429–435. doi: 10.1016/j.joms.2016.08.011
- Lin A, Stapelmann K, Bogaerts A. Advances in plasma oncology toward clinical translation. Cancers. 2020;12(11):32–83. EDN: OPIETN doi: 10.3390/cancers12113283
- Li X, Rui X, Li D, et al. Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma. Front Oncol. 2022;29(12):994172. EDN: JMEUID doi: 10.3389/fonc.2022.994172
- Dejonckheere CS, Torres-Crigna A, Layer JP, et al. Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: A first-in-human feasibility study. Pharmaceutics. 2022;14(9):1767. EDN: MHPUEP doi: 10.3390/pharmaceutics14091767
Supplementary files
